Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity

Dianying Zhang; Jingjing Zhao; Yujing Zhang; Hongfei Jiang; Dan Liu

doi:10.3389/fimmu.2024.1490129

Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity

Front Immunol. 2024 Dec 10:15:1490129. doi: 10.3389/fimmu.2024.1490129. eCollection 2024.

Authors

Dianying Zhang^#¹, Jingjing Zhao^#^{2

3}, Yujing Zhang⁴, Hongfei Jiang⁵, Dan Liu¹

Affiliations

¹ Medical Education Department, Guangdong Provincial People's Hospital, Zhuhai Hospital (Jinwan Central Hospital of Zhuhai), Zhuhai, China.
² Sleep Medicine Center, Huai'an No.3 People's Hospital, Huai'an, China.
³ Huaian Second Clinical College of Xuzhou Medical University, Huaian, China.
⁴ The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao University, Qingdao, Shandong, China.
⁵ The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, Shandong, China.

^# Contributed equally.

No abstract available

Keywords: biomarker-guided therapy; cancer therapy; combination therapies; immune checkpoint inhibitors; immune-related adverse events (irAEs).

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by Huai’an natural science research program (HAB202216).